Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Tigecycline In-vitro Surveillance in Taiwan (TIST), initiated in 2006, is a nationwide surveillance programme designed to monitor longitudinally the in-vitro activity of tigecycline against commonly encountered resistant bacteria. This study compared the in-vitro activity of tigecycline against clinical isolates of resistant Gram-negative bacteria determined by the broth microdilution and Etest methods. A total of 622 isolates were collected from patients treated at 20 teaching hospitals. Tigecycline had excellent in-vitro activity against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (N = 275) with MIC(90) 0.5 microg/mL and a 99.6% susceptibility rate, and also against ESBL-producing Klebsiella pneumoniae (N = 324) with MIC(90) 2 microg/mL and a 98.5% susceptibility rate. For ESBL-producing Proteus mirabilis (N = 15) the MIC(90) was 4 microg/mL with a 73.3% susceptibility rate. For ESBL-producing Klebsiella oxytoca (N = 8) the MIC(50) and MIC(90) were 0.5 and 1 microg/mL, respectively, with a 100% susceptibility rate. Limited agreement (<80%) was found between the broth microdilution and the Etest methods when determining the in-vitro activity of tigecycline against ESBL- producing K. pneumoniae and K. oxytoca.
Lu
Chin-Te
CT
Department of Internal Medicine, Lotung Poh-Ai Hospital, Yilan, Taiwan.
Chuang
Yin-Ching
YC
Sun
Wu
W
Liu
Yung-Ching
YC
Cheng
Yu-Jen
YJ
Lu
Po-Liang
PL
Chen
Chih-Ming
CM
Hsu
Gwo-Jong
GJ
Jang
Tsrang-Neng
TN
Lee
Chun-Ming
CM
Chiang
Ping-Cherng
PC
Shi
Zhi-Yuan
ZY
Wang
Lih-Shinn
LS
Kung
Hsiang-Chi
HC
Lin
Hsiu-Chen
HC
Liao
Chun-Hsing
CH
Liu
Jien-Wei
JW
Huang
Cheng-Hua
CH
Tsao
Shih-Ming
SM
Hsueh
Po-Ren
PR
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification*; D004756:Enterobacteriaceae Infections / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D013624:Taiwan; D000078304:Tigecycline; D001618:beta-Lactamases / Q000096:biosynthesis*
D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D001618:beta-Lactamases; D008911:Minocycline